Neurology Center of San Antonio
San Antonio, Texas 78258
0 studies enrolling now · 14 studies all time
What they study most
Cervical Dystonia, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Relapsing Multiple Sclerosis
Studies at this site
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Running, not enrolling
- A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) — Completed
- A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS) — Completed
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis — Completed
- Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS) — Stopped early
- Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) — Stopped early
- DYSPORT™ Clinical & Health Economics Outcomes Registry in Cervical Dystonia — Completed
- A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) — Completed
- Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis — NO_LONGER_AVAILABLE
- An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab — Completed
- Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two — Completed
- A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis — Completed
- Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One — Completed
- Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy — Completed